Trial Profile

Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With COVID-19 Pneumonia

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 17 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Reparixin (Primary) ; Reparixin (Primary)
Indications COVID 2019 infections; COVID-19 pneumonia; Respiratory insufficiency
Focus Therapeutic Use
Acronyms REPAVID-19
Sponsors Dompe Farmaceutici

Most Recent Events

13 Jun 2022 According to a Dompe Farmaceutici media release, results from this trial were presented at the scientific sessions of the American Thoracic Society 2022 International Conference.
13 Jun 2022 Results published in the Dompe Farmaceutici Media Release.
26 May 2022 Primary endpoint has been met. (Phase 2 - Percentage of Participants With Composite Endpoint of Clinical Events), as per Results published in the Infectious Diseases and Therapy

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com